IP Library › Granted Patent US 7,704,997

Granted Patent B1

US 7,704,997 · App. 11/221,333 · Granted Apr 27, 2010

Amino-tetrazole analogues and methods of use

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,704,997
App. No.: 11/221,333
Granted: Apr 27, 2010
Kind: B1

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

A compound having Formula (I) or Formula (II) is disclosed as an P2X 7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R 1 , R 2 , R 3 , R 4 , and R 5 , are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X 7 are also disclosed.

Claims (286)

1. A compound having Formula (I),

or a therapeutically acceptable salt thereof, in which

R 2 is phenyl, in which each R 2 is substituted with one, two, three, four, or five substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NH 2 , —R 2a , —OR 2a , —NHR 2a , —N(R 2a ) 2 , —CN, —SR 2a , and —SO 2 R 2a ;

R 2a is —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 2b ;

R 2b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —Br, —I, —F, —Cl, —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —NH 2 , —NHR 2c , —N(R 2c ) 2 , —CN, —SR 2c , and —SO 2 R 2c ;

R 2c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

m is 1;

X and Y is —H; or

X and Y together with the carbon atom to which they are attached form a ring selected from the group consisting of cyclopropane, cyclobutane, cyclopentane, cyclohexane, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, dioxolane, tetrahydropyran, piperidine, morpholine, thiomorpholine, and piperazine, each or which is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NH 2 , —R 2a , —OR 2a , —NHR 2a , —N(R 2a) 2 , —CN, —SR 2a , and —SO 2 R 2a ;

Z is —H; or

Z and X together with the atoms to which they are attached form a ring selected from the group consisting of pyrrolidine, piperidine, morpholine, thiomorpholine, and piperazine;

R 1 is

pyridyl, which is unfused or fused with a ring selected from the group consisting of cyclopentane, cyclohexane, cyclopentene, cyclohexene, naphthalene, benzene, furan, imidazole, isothiazole, oxazole, isoxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, tetrahydrofuran, tetrahydrothiophene, thiazole, thiophene, pyrrolidine, dioxolane, pyrazolidine, pyran, piperidine, morpholine, thiomorpholine, and piperazine wherein each ring is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of of —Cl, —F, —Br, —I, —OH, —NH 2 , —NO 2 , —R 1a , —OR 1a , —NHR 1a , —N(R 1a ) 2 , —CN, —SR 1a , —SO 2 R 1a , —SO 2 NH 2 , —SO 2 N(H)(R 1a ), —SO 2 N(R 1a ) 2 , —C(O)R 1a , —C(O)OH, —C(O)OR 1a , —C(O)NH 2 , —C(O)N(H)(R 1a ), —C(O)N(R 1a ) 2 , —OR 1e , —SR 1e , —SO 2 R 1e , —SO 2 N(H)(R 1e ), —SO 2 N(R 1d )(R 1e )—NH(R 1e ), —N(R 1d )(R 1e ), —NHC(O)R 1f , —N(R 1d )C(O)R 1f , and —R 1c ;

R 1a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or —R 1b ;

R 1b is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NH 2 , —OH, —OR 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —R 1c , —N(R 1d ) 2 , and —NHR 1d ;

R 1c is cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocycle, in which each R 1c is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —NO 2 , —CN, —OH, —R 1aa , —NH 2 , —OR 1aa , —SR 1aa , —NHR 1aa , —N(R 1aa ) 2 , —C(O)R 1aa , —S(O) 2 R 1aa , —S(O) 2 NH 2 , —S(O) 2 N(R 1aa ) 2 , —C(O)NH 2 , —C(O)N(H)(R 1aa ), —C(O)N(R 1aa ) 2 , —C(O)OH, —C(O)OR 1aa , —OR 1h , —N(H)R 1h ), —N(R 1d )(R 1h ) and —R 1h ;

R 1aa is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or —R 1bb ;

R 1bb is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NO 2 , —CN, haloalkyl, haloalkoxy, —NH 2 , —OH, —OR 1d , —SR 1d , —S(O) 2 R 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —N(R 1d ) 2 , —NHR 1d , —C(O)OH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), —C(O)N(R 1d ) 2 , —S(O) 2 NH 2 , —S(O) 2 N(H)(R 1d ), —S(O) 2 N(R 1d ) 2 and —R 1h ;

R 1d is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 1e is a monocyclic or bicyclic ring selected from the group consisting of cycloalkyl, heterocycle, aryl and heteroaryl, wherein each ring is unsubstituted or substituted with one, two, three or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —NO 2 , —CN, —OH, —R 1aa , —OR 1aa , —SR 1aa , —NH 2 , —NHR 1aa , and —N(R 1aa ) 2 ;

R 1f is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, aryl, heteroaryl, —R 1h , or R 1g ;

R 1g is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one substituent selected from the group consisting —R 1h ; R 1h is cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocycle, in which each R 1h is unsubstituted or substituted with one or two or three or four or five substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NO 2 , —CN, haloalkyl, haloalkoxy, —NH 2 , —OH, —OR 1d , —SR 1d , —S(O) 2 R 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —N(R 1d ) 2 , —NHR 1d , —C(O)OH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), —C(O)N(R 1d ) 2 , —S(O) 2 NH 2 , —S(O) 2 N(H)(R 1d ), and —S(O) 2 N(R 1d ) 2 .

2. A compound having Formula (I),

or a therapeutically acceptable salt thereof, in which

R 2 is phenyl, wherein each R 2 is substituted with one, two, three, four, or five substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NH 2 , —R 2a , —OR 2a , —NHR 2a , —N(R 2a ) 2 , —CN, —SR 2a , and —SO 2 R 2a ;

R 2a is —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 2b ;

R 2c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

m is 1;

X and Y is —H; or

Z is —H; or

Z and X together with the atoms to which they are attached form a ring selected from the group consisting of pyrrolidine, piperidine, morpholine, thiomorpholine, and piperazine;

R 1 is

pyridyl which is unfused or fused with a ring selected from the group consisting of cyclopentane, cyclohexane, cyclopentene, cyclohexene, naphthalene, benzene, furan, imidazole, isothiazole, oxazole, isoxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, tetrahydrofuran, tetrahydrothiophene, thiazole, thiophene, pyrrolidine, dioxolane, pyrazolidine, pyran, piperidine, morpholine, thiomorpholine, and piperazine, wherein each ring is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NO 2 , —OH, —NH 2 , —R 1a , —OR 1a —NHR 1a , —N(R 1a ) 2 , —CN, —SR 1a , —SO 2 R 1a , —SO 2 NH 2 —SO 2 N(H)(R 1a ), —SO 2 N(R 1a ) 2 , —C(O)R 1a , —C(O)OH, —C(O)OR 1a , —C(O)NH 2 , —C(O)N(H)(R 1a ), —C(O)N(R 1a ) 2 , —OR 1e , —SR 1e , —SO 2 R 1e , —SO 2 N(H)(R 1e ), —SO 2 N(R 1d )(R 1e ), —NH(R 1e ), —N(R 1d )(R 1e ), —NHC(O)R 1f , —N(R 1d )C(O)R 1f , and —R 1c ;

R 1a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or —R 1b ;

R 1c is cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, azetidinyl, naphthyl, quinolinyl, isoquinolinyl, phenyl, furyl, imidazolyl, isothiazolyl, oxazolyl, oxazolinyl, isoxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, imidazolinyl, tetrahydrofuryl, tetrahydrothienyl thiazolyl, thienyl, pyrrolidinyl, dioxolanyl, pyrazolinyl, pyrazolidinyl, pyranyl, piperidyl, morpholinyl, thiomorpholinyl, piperazinyl, 2-azabicyclo[2.2.2]octyl, 2-oxa-5-azabicyclo[2.2.2]octyl, 2,5-diazabicyclo[2.2.2]octyl, 2-azabicyclo[2.2.1]heptyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.1.1]hexyl, 5-azabicyclo[2.1.1]hexyl, 3-azabicyclo[3.2.0]heptyl, 3,6-diazabicyclo[3.2.0]heptyl, octahydrocyclopenta[c]pyrrolyl, hexahydro-1H-furo[3,4-c]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl, 3-azabicyclo[3.1.1]heptyl, 6-oxa-3-azabicyclo[3.1.1]heptyl, octahydro-1H-4,7-methanoisoindolyl, octahydro-1H-4,7-epoxyisoindolyl, 8-azabicyclo[3.2.1]octyl, 3-oxa-8-azabicyclo[3.2.1]octyl, 1,4-diazepanyl, 1,4-diazabicyclo[3.2.2]nonyl, 1,4-diazatricyclo[4.3.1.1 3,8 ]undecyl, 3,10-diazabicyclo[4.3.1]decyl, or 8-oxa-3-azabicyclo[3.2.1]octyl, each of which is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, ═O, —NO 2 , —CN, —OH, —R 1aa , —NH 2 , —OR 1aa , —SR 1aa , —NHR 1aa , —N(R 1aa ) 2 , —C(O)R 1aa , S(O) 2 R 1aa , S(O) 2 NH 2 , S(O) 2 N(R 1aa ) 2 , —C(O)NH 2 , —C(O)N(H)(R 1aa ), —C(O)N(R 1aa ) 2 , —C(O)OH, —C(O)OR 1aa , —OR 1h , —N(H)R 1b ), —N(R 1d )(R 1h ) and R 1h ;

R 1aa is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or —R 1bb ;

R 1bb is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NO 2 , —CN, haloalkyl, haloalkoxy, —NH 2 , —OH, —OR 1d , —SR 1d , —S(O) 2 R 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —N(R 1d ) 2 , —NHR 1d ; —C(O)OH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), —C(O)N(R 1d ) 2 , —S(O) 2 NH 2 , —S(O) 2 N(H)(R 1d ), —S(O) 2 N(R 1d ) 2 and —R 1h ;

R 1d is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 1e is phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, furyl, thienyl, imidazolyl, thiazolyl, pyrrolidinyl, piperidyl, azepinyl, tetrahydrofuryl, tetrahydropyranyl or oxazolyl; wherein each R 1e is unsubstituted or substituted with one, two, three or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —NO 2 , —CN, —OH, —R 1aa , —OR 1aa , —SR 1aa , —NH 2 , —NHR 1aa , and —N(R 1aa ) 2 ;

R 1f is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, aryl, heteroaryl, —R 1h , or R 1g ;

R 1g is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one substituent selected from the group consisting of aryl and heteroaryl;

R 1h is cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocycle, in which each R 1h is unsubstituted or substituted with one or two or three or four or five substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NO 2 , —CN, haloalkyl, haloalkoxy, —NH 2 , —OH, —OR 1d , —SR 1d , —S(O) 2 R 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —N(R 1d ) 2 , —NHR 1d , —C(O)OH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), —C(O)N(R 1d ) 2 , —S(O) 2 NH 2 , —S(O) 2 N(H)(R 1d ), and —S(O) 2 N(R 1d ) 2 .

3. The compound of claim 1 having Formula (I),

or a therapeutically acceptable salt thereof, in which

R 2a is —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 2b ;

R 2c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

m is 1;

X and Y is H; or

X and Y together with the carbon atom to which they are attached form a ring selected from the group consisting of cyclopropane, cyclobutane, cyclopentane, cyclohexane, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, dioxolane, tetrahydropyran, piperidine, morpholine, thiomorpholine, and piperazine, each of which is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NH 2 , —R 2a , —OR 2a , —NHR 2a , —N(R 2a ) 2 , —CN, —SR 2a , and —SO 2 R 2a ;

Z is —H; or

Z and X together with the atoms to which they are attached form a ring selected from the group consisting of pyrrolidine, piperidine, morpholine, thiomorpholine, and piperazine;

R 1 is

pyridyl which is unfused or fused with a ring selected from the group consisting of cyclopentane, cyclohexane, cyclopentene, cyclohexene, naphthalene, benzene, furan, imidazole, isothiazole, oxazole, isoxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, tetrahydrofuran, tetrahydrothiophene, thiazole, thiophene, pyrrolidine, dioxolane, pyrazolidine, pyran, piperidine, morpholine, thiomorpholine, and piperazine, wherein each ring is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —OH, —NO 2 , —NH 2 , —R 1a , —OR 1a , —NHR 1a , —N(R 1a ) 2 , —CN, —SR 1a , —SO 2 R 1a , —SO 2 NH 2 , —SO 2 N(H)(R 1a ), —SO 2 N(R 1a ) 2 , —C(O)R 1a , —C(O)OH, —C(O)OR 1a , —C(O)NH 2 , —C(O)N(H)(R 1a ), —C(O)N(R 1a ) 2 , —OR 1e , —SR 1e , —SO 2 R 1e , —SO 2 N(H)(R 1e ), —SO 2 N(R 1d )(R 1e ), —NH(R 1e ), —N(R 1d )(R 1e ), —NHC(O)R 1f , —N(R 1d )C(O)R 1f , and —R 1c ;

R 1a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or —R 1b ;

R 1c is cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, azetidinyl, naphthyl, quinolinyl, isoquinolinyl, phenyl, furyl, imidazolyl, isothiazolyl, oxazolyl, oxazolinyl, isoxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, imidazolinyl, tetrahydrofuryl, tetrahydrothienyl thiazolyl, thienyl, pyrrolidinyl, dioxolanyl, pyrazolinyl, pyrazolidinyl, pyranyl, piperidyl, morpholinyl, thiomorpholinyl, piperazinyl, 2-azabicyclo[2.2.2]octyl, 2-oxa-5-azabicyclo[2.2.2]octyl, 2,5-diazabicyclo[2.2.2]octyl, 2-azabicyclo[2.2.1]heptyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.1.1]hexyl, 5-azabicyclo[2.1.1]hexyl, 3-azabicyclo[3.2.0]heptyl, 3,6-diazabicyclo[3.2.0]heptyl, octahydrocyclopenta[c]pyrrolyl, hexahydro-1H-furo[3,4-c]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl, 3-azabicyclo[3.1.1]heptyl, 6-oxa-3-azabicyclo[3.1.1]heptyl, octahydro-1H-4,7-methanoisoindolyl, octahydro-1H-4,7-epoxyisoindolyl, 8-azabicyclo[3.2.1]octyl, 3-oxa-8-azabicyclo[3.2.1]octyl, 1,4-diazepanyl, 1,4-diazabicyclo[3.2.2]nonyl, 1,4-diazatricyclo[4.3.1.1 3,8 ]undecyl, 3,10-diazabicyclo[4.3.1]decyl, or 8-oxa-3-azabicyclo[3.2.1]octyl, each of which is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —NO 2 , —CN, —OH, —R 1aa , —NH 2 , —OR 1aa , —SR 1aa , —NHR 1aa , —N(R 1aa ) 2 , —C(O)R 1aa , —S(O) 2 R 1aa , —S(O) 2 NH 2 , —S(O) 2 N(R 1aa ) 2 , —C(O)NH 2 , —C(O)N(H)(R 1aa ), —C(O)N(R 1aa ) 2 , —C(O)OH, —C(O)OR 1aa , —OR 1h , —N(H)R 1h ), —N(R 1d )(R 1h ) and —R 1h ;

R 1aa is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or —R 1bb ;

R 1d is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 1f is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, aryl, heteroaryl, —R 1h , or R 1g ;

R 1g is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one substituent selected from the group consisting of R 1h ;

4. The compound of claim 3 , or a therapeutically acceptable salt thereof, in which

R 2 is phenyl substituted with one, two, three, four, or five substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NH 2 , —R 2a , —OR 2a , —NHR 2a , —N(R 2a ) 2 , —CN, —SR 2a , and —SO 2 R 2a ;

R 2a is —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 2b ;

R 2c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl,

R 1 is

pyridyl which is unfused or fused with a ring selected from the group consisting of cyclopentane, cyclohexane, cyclopentene, cyclohexene and a benzene, wherein each ring is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NO 2 , —OH, —NH 2 , —R 1a , —OR 1a , —NHR 1a , —N(R 1a ) 2 , —CN, —SR 1a , —SO 2 R 1a , —SO 2 NH 2 , —SO 2 N(H)(R 1a ), —SO 2 N(R 1a ) 2 , —C(O)R 1a , —C(O)OH, —C(O)OR 1a , —C(O)NH 2 , —C(O)N(H)(R 1a ), —C(O)N(R 1a ) 2 , —OR 1e , —SR 1e , —SO 2 R 1e , —SO 2 N(H)(R 1e ), —SO 2 N(R 1d )(R 1e ), —NH(R 1e ), —N(R 1d )(R 1e ), —NHC(O)R 1f , —N(R 1d )C(O)R 1f , and —R 1c ;

R 1a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or —R 1b ;

R 1c is cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, azetidinyl, naphthyl, quinolinyl, isoquinolinyl, phenyl, furyl, imidazolyl, isothiazolyl, oxazolyl, oxazolinyl, isoxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, imidazolinyl, tetrahydrofuryl, tetrahydrothienyl thiazolyl, thienyl, pyrrolidinyl, dioxolanyl, pyrazolinyl, pyrazolidinyl, pyranyl, piperidyl, morpholinyl, thiomorpholinyl, piperazinyl, 2-azabicyclo[2.2.2]octyl, 2-oxa-5-azabicyclo[2.2.2]octyl, 2,5-diazabicyclo[2.2.2]octyl, 2-azabicyclo[2.2.1]heptyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.1.1]hexyl, 5-azabicyclo[2.1.1]hexyl, 3-azabicyclo[3.2.0]heptyl, 3,6-diazabicyclo[3.2.0]heptyl, octahydrocyclopenta[c]pyrrolyl, hexahydro-1H-furo[3,4-c]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl, 3-azabicyclo[3.1.1]heptyl, 6-oxa-3-azabicyclo[3.1.1]heptyl, octahydro-1H-4,7-methanoisoindolyl, octahydro-1H-4,7-epoxyisoindolyl, 8-azabicyclo[3.2.1]octyl, 3-oxa-8-azabicyclo[3.2.1]octyl, 1,4-diazepanyl, 1,4-diazabicyclo[3.2.2]nonyl, 1,4-diazatricyclo[4.3.1.1 3,8 ]undecyl, 3,10-diazabicyclo[4.3.1]decyl, or 8-oxa-3-azabicyclo[3.2.1]octyl, each of which is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —NO 2 , —CN, —OH, —R 1aa , —SR 1aa , —NH 2 , —OR 1aa , —NHR 1aa , —N(R 1aa ) 2 —C(O)R 1aa , —S(O) 2 R 1aa , —S(O) 2 NH 2 , —S(O) 2 N(R 1aa ) 2 , —C(O)NH 2 , —C(O)N(H)(R 1aa ), —C(O)N(R 1aa ) 2 , —C(O)OH, —C(O)OR 1aa , —OR 1h , —N(H)R 1h ), —N(R 1d )(R 1h ) and —R 1h ;

R 1aa is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or —R 1bb ;

R 1bb is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NO 2 , —CN, haloalkyl, haloalkoxy, —NH 2 , —OH, —OR 1d , —SR 1d , —S(O) 2 R 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —N(R 1d ) 2 , —NHR 1d —C(O)OH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), —C(O)N(R 1d ) 2 , —S(O) 2 NH 2 , —S(O) 2 N(H)(R 1d ), —S(O) 2 N(R 1d ) 2 and —R 1h ;

R 1d is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 1f is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, aryl, heteroaryl, —R 1h , or R 1g ; and

R 1g is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one substituent selected from the group consisting of —R 1h , R 1h is cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocycle, in which each R 1h is unsubstituted or substituted with one or two or three or four or five substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NO 2 , —CN, haloalkyl, haloalkoxy, —NH 2 , —OH, —OR 1d , —SR 1d , —S(O) 2 R 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —N(R 1d ) 2 , —NHR 1d , —C(O)OH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), —C(O)N(R 1d ) 2 , —S(O) 2 NH 2 , —S(O) 2 N(H)(R 1d ), and —S(O) 2 N(R 1d ) 2 .

5. The compound of claim 3 , or a therapeutically acceptable salt thereof, in which

R 2 is phenyl substituted with one, two, three, four, or five substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —NH 2 , —R 2a , —OR 2a , —NHR 2a , —NHR 2a , —N(R 2a ) 2 , —CN, —SR 2a , and —SO 2 R 2a ;

R 2a is —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or R 2b ;

R 2c is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl,

R 1 is

pyridyl, which is unfused and unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of —Cl, —F, —Br, —I, —OH, —NO 2 , —NH 2 , —R 1a , —OR 1a , —NHR 1a , —N(R 1a ) 2 , —CN, —SR 1a , —SO 2 R 1a , —SO 2 NH 2 , —SO 2 N(H)(R 1a ), —SO 2 N(R 1a ) 2 , —C(O)R 1a , —C(O)OH, —C(O)OR 1a , —C(O)NH 2 , —C(O)N(H)(R 1a ), —C(O)N(R 1a ) 2 , —OR 1e , —SR 1e , —SO 2 R 1e , —SO 2 N(H)(R 1e ), —SO 2 N(R 1d )(R 1e ), —NH(R 1e ), —N(R 1d )(R 1e ), —NH(R 1e ), —N(R 1d )(R 1e ), —NHC(O)R 1f , —N(R 1d )C(O)R 1f , and —R 1c ;

R 1a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or —R 1b ;

R 1c is cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, azetidinyl, naphthyl, quinolinyl, isoquinolinyl, phenyl, furyl, imidazolyl, isothiazolyl, oxazolyl, oxazolinyl, isoxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, imidazolinyl, tetrahydrofuryl, tetrahydrothienyl thiazolyl, thienyl, pyrrolidinyl, dioxolanyl, pyrazolinyl, pyrazolidinyl, pyranyl, piperidyl, morpholinyl, thiomorpholinyl, piperazinyl, 2-azabicyclo[2.2.2]octyl, 2-oxa-5-azabicyclo[2.2.2]octyl, 2,5-diazabicyclo[2.2.2]octyl, 2-azabicyclo[2.2.1]heptyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.1.1]hexyl, 5-azabicyclo[2.1.1]hexyl, 3-azabicyclo[3.2.0]heptyl, 3,6-diazabicyclo[3.2.0]heptyl, octahydrocyclopenta[c]pyrrolyl, hexahydro-1H-furo[3,4-c]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl, 3-azabicyclo[3.1.1]heptyl, 6-oxa-3-azabicyclo[3.1.1]heptyl, octahydro-1H-4,7-methanoisoindolyl, octahydro-1H-4,7-epoxyisoindolyl, 8-azabicyclo[3.2.1]octyl, 3-oxa-8-azabicyclo[3.2.1]octyl, 1,4-diazepanyl, 1,4-diazabicyclo[3.2.2]nonyl, 1,4-diazatricyclo[4.3.1.1 3,8 ]undecyl, 3,10-diazabicyclo[4.3.1]decyl, or 8-oxa-3-azabicyclo[3.2.1]octyl, each of which is unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of ═O, —Cl, —F, —Br, —I, —NO 2 , —CN, —OH, —R 1aa , —SR 1aa , —NH 2 , —OR 1aa , —NHR 1aa , —N(R 1aa ) 2 —C(O)R 1aa , —S(O) 2 R 1aa , —S(O) 2 NH 2 , —S(O) 2 N(R 1aa ) 2 , —C(O)NH 2 , —C(O)N(H)(R 1aa ), —C(O)N(R 1aa ) 2 , —C(O)OH, —C(O)OR 1aa , —OR 1h , —N(H)R 1h ), —N(R 1d )(R 1h ) and —R 1h ;

R 1aa is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, or —R 1bb ;

R 1bb is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one or two or three substituents independently selected from the group consisting of —F, —Cl, —Br, —I, —NO 2 , —CN, haloalkyl, haloalkoxy, —NH 2 , —OH, —OR 1d , —SR 1d , —S(O) 2 R 1d , —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, —N(R 1d ) 2 , —NHR 1d —C(O)OH, —C(O)OR 1d , —C(O)NH 2 , —C(O)N(H)(R 1d ), —C(O)N(R 1d ) 2 , —S(O) 2 NH 2 , —S(O) 2 N(H)(R 1d ), —S(O) 2 N(R 1d ) 2 and —R 1h ;

R 1d is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

R 1f is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, —C 6 -alkyl, aryl, heteroaryl, —R 1h , or R 1g ;

R 1g is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl, each of which is substituted with one substituent selected from the group consisting of R 1h ; and

6. The compound of claim 3 , or a therapeutically acceptable salt thereof, in which

R 2 is phenyl substituted with two substituents independently selected from the group consisting of —Cl, —F, —Br, —I and R 2a ;

R 2a is —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl, or —C 6 -alkyl;

m is 1;

X and Y is —H;

Z is —H;

R 1 is

(a) unfused pyridyl, unsubstituted or substituted with one —R 1a substituent; or

(b) pyridyl fused with a distal cyclopentane, cyclohexane, or benzene, wherein each ring is unsubstituted or substituted with one —R 1a substituent; and

R 1a is —C 1 -alkyl, —C 2 -alkyl, —C 3 -alkyl, —C 4 -alkyl, —C 5 -alkyl or —C 6 -alkyl.

7. The compound of claim 3 , or a therapeutically acceptable salt thereof, in which

R 2 is phenyl substituted with two substituents independently selected from the group consisting of —Cl and —C 1 -alkyl;

m is 1;

X and Y is —H;

Z is H; and

R 1 is

(a) unfused pyridyl, unsubstituted or substituted with one —C 1 -alkyl substituent; or

(b) pyridyl fused with a ring selected from the group consisting of cyclopentane, cyclohexane, or benzene, wherein each ring is unsubstituted or substituted with one —C 1 -alkyl substituent.

8. The compound of claim 3 , or a therapeutically acceptable salt thereof, selected from the group consisting of:

1-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-(quinolin-4-ylmethyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(3-methylpyridin-4-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-(6,7-dihydro-5H-cyclopenta[b]pyridin-3-ylmethyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-(5,6,7,8-tetrahydroquinolin-3-ylmethyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-methylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-phenoxypyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-methoxypyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2,2,2-trifluoroethoxy)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-(quinolin-3-ylmethyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-({2-[(6-methylpyridin-3-yl)oxy]pyridin-3-yl}methyl)-1H-tetrazol-5-amine;

N-({6-chloro-5-fluoro-2-[(1-methylpyrrolidin-3-yl)oxy]pyridin-3-yl}methyl)-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-(pyridin-2-ylmethyl)-1H-tetrazol-5-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[2-(1-methyl-piperidin-4-yloxy)-pyridin-3-ylmethyl]-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[2-(1-methyl-piperidin-3-yloxy)-pyridin-3-ylmethyl]-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[2-(1-methyl-pyrrolidin-3-yloxy)-pyridin-3-ylmethyl]-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[2-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-ylmethyl]-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[2-(2-methyl-pyridin-3-yloxy)-pyridin-3-ylmethyl]-amine;

[2-(5-Chloro-pyridin-3-yloxy)-pyridin-3-ylmethyl]-[1-(2,3-dichloro-phenyl)-1H-tetrazol-5-yl]-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[6-methyl-2-(pyridin-3-yloxy)-pyridin-3-ylmethyl]-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[2-(pyridin-3-yloxy)-pyridin-3-ylmethyl]-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[2-(5-fluoro-pyridin-3-yloxy)-pyridin-3-ylmethyl]-amine;

[2-(2-Chloro-pyridin-3-yloxy)-pyridin-3-ylmethyl]-[1-(2,3-dichloro-phenyl)-1H-tetrazol-5-yl]-amine;

[2-(6-Chloro-5-fluoro-pyridin-3-yloxy)-pyridin-3-ylmethyl]-[1-(2,3-dichloro-phenyl)-1H-tetrazol-5-yl]-amine;

[6-Chloro-5-fluoro-2-(2,2,2-trifluoro-ethoxy)-pyridin-3-ylmethyl]-[1-(2,3-dichloro-phenyl)-1H-tetrazol-5-yl]-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-(6-fluoro-2-methyl-pyridin-3-ylmethyl)-amine;

1-(2,3-dichlorophenyl)-N-[(2-morpholin-4-ylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[6-(trifluoromethyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-ethylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-fluoropyridin-3-yl)methyl]-1H-tetrazol-5-amine;

N-[(2-chloro-5-fluoropyridin-3-yl)methyl]-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(3-fluoropyridin-4-yl)methyl]-1H-tetrazol-5-amine;

N-[(3-chloropyridin-4-yl)methyl]-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-[2-fluoro-3-(trifluoromethyl)phenyl]-N-{[2-(2,2,2-trifluoroethoxy)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2,6-dimethylmorpholin-4-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichloro-4-fluorophenyl)-N-{[2-(pyridin-3-yloxy)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

N-[(2-chloropyridin-3-yl)methyl]-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

N-[(2-bromopyridin-3-yl)methyl]-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-fluoropyridin-4-yl)methyl]-1H-tetrazol-5-amine;

N-[(2-bromopyridin-4-yl)methyl]-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-pyrrolidin-1-ylpyridin-4-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-phenylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(4-ethoxyphenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(4-fluorophenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(4-methylphenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

N-{[2-(4-chlorophenyl)pyridin-3-yl]methyl}-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

N-{[2-(3-chlorophenyl)pyridin-3-yl]methyl}-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(3-methylphenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2-methoxyphenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(3,4-difluorophenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2-fluorophenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-({2-[3-(trifluoromethoxy)phenyl]pyridin-3-yl}methyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2-methylphenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(3-fluorophenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-({2-[4-(trifluoromethoxy)phenyl]pyridin-3-yl}methyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-({2-[2-(trifluoromethoxy)phenyl]pyridin-3-yl}methyl)-1H-tetrazol-5-amine;

N-{[2-(2-chlorophenyl)pyridin-3-yl]methyl}-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2-phenoxyphenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-({2-[2-(trifluoromethyl)phenyl]pyridin-3-yl}methyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-thien-2-ylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-thien-3-ylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

N-(2,3′-bipyridin-3-ylmethyl)-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

N-(2,4′-bipyridin-3-ylmethyl)-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(1,3-thiazol-2-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[5-fluoro-2-(4-fluorophenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2-methoxyphenyl)-6-(trifluoromethyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(5-fluoro-2-methoxyphenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(4-fluoro-2-methoxyphenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2-fluoro-6-methoxyphenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2,4-difluorophenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2,3-difluorophenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2,5-difluorophenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2,4,6-trifluorophenyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-pyrrolidin-1-ylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-piperidin-1-ylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

N-[(2-azetidin-1-ylpyridin-3-yl)methyl]-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(3-pyrrolidin-1-ylpyridin-4-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(5-fluoro-2-pyrrolidin-1-ylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

N-benzyl-3-({[1-(2,3-dichlorophenyl)-1H-tetrazol-5-yl]amino}methyl)pyridin-2-amine;

1-(2,3-dichlorophenyl)-N-{[2-(3,3-difluoroazetidin-1-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

N-[(2-chloro-3-pyrrolidin-1-ylpyridin-4-yl)methyl]-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

N-[(2-azetidin-1-yl-5-fluoropyridin-3-yl)methyl]-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2,5-difluoro-6-pyrrolidin-1-ylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-[(2-phenyl-3-pyrrolidin-1-ylpyridin-4-yl)methyl]-1H-tetrazol-5-amine;

N-[(2-azepan-1-ylpyridin-3-yl)methyl]-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-pyrrolidin-1-yl-6-(trifluoromethyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

N-benzyl-3-({[1-(2,3-dichlorophenyl)-1H-tetrazol-5-yl]amino}methyl)-N-methylpyridin-2-amine;

1-(2,3-dichloro-4-fluorophenyl)-N-[(6′-fluoro-2,3′-bipyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-[2-chloro-4-fluoro-3-(trifluoromethyl)phenyl]-N-[(2-fluoropyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-[4-chloro-2-fluoro-3-(trifluoromethyl)phenyl]-N-[(2-fluoropyridin-3-yl)methyl]-1H-tetrazol-5-amine;

N-[(2-fluoropyridin-3-yl)methyl]-1-(2,3,4-trichlorophenyl)-1H-tetrazol-5-amine;

N-[(2-fluoropyridin-3-yl)methyl]-1-(2,3,5-trichlorophenyl)-1H-tetrazol-5-amine;

1-[2,3-bis(trifluoromethyl)phenyl]-N-[(2-fluoropyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichloro-4-fluorophenyl)-N-[(2-fluoropyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichloro-4-fluorophenyl)-N-[(2-thien-3-ylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

N-[(2-azetidin-1-yl-5-fluoropyridin-3-yl)methyl]-1-(2,3-dichloro-4-fluorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichloro-4-fluorophenyl)-N-{[2-(4-methyl-1,4-diazepan-1-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

N-(2,3′-bipyridin-3-ylmethyl)-1-(2,3-dichloro-4-fluorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(trifluoromethyl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

N-{[2-(3-azabicyclo[3.2.2]non-3-yl)pyridin-3-yl]methyl}-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(3,3-difluoropiperidin-1-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(4,4-difluoropiperidin-1-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-({2-[4-(trifluoromethyl)piperidin-1-yl]pyridin-3-yl}methyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(3-fluoropiperidin-1-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(4-fluoropiperidin-1-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-({2-[3-(trifluoromethyl)pyrrolidin-1-yl]pyridin-3-yl}methyl)-1H-tetrazol-5-amine;

1-[3-({[1-(2,3-dichlorophenyl)-1H-tetrazol-5-yl]amino}methyl)pyridin-2-yl]pyrrolidin-3-ol;

1-(2,3-dichlorophenyl)-N-{[2-(3,3-difluoropyrrolidin-1-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2-methylpyrrolidin-1-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(2,5-dimethylpyrrolidin-1-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(1,4-oxazepan-4-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-{[2-(4-methyl-1,4-diazepan-1-yl)pyridin-3-yl]methyl}-1H-tetrazol-5-amine;

tert-butyl 4-[3-({[1-(2,3-dichlorophenyl)-1H-tetrazol-5-yl]amino}methyl)pyridin-2-yl]-1,4-diazepane-1-carboxylate;

N-{[2-(1,4-diazepan-1-yl)pyridin-3-yl]methyl}-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

tert-butyl 3-[3-({[1-(2,3-dichlorophenyl)-1H-tetrazol-5-yl]amino}methyl)pyridin-2-yl]-3,6-diazabicyclo[3.2.0]heptane-6-carboxylate;

N-{[2-(3,6-diazabicyclo[3.2.0]hept-3-yl)pyridin-3-yl]methyl}-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

benzyl (1S,5S)-6-[3-({[1-(2,3-dichlorophenyl)-1H-tetrazol-5-yl]amino}methyl)pyridin-2-yl]-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate;

N-({2-[(1R,5S)-3,6-diazabicyclo[3.2.0]hept-6-yl]pyridin-3-yl}methyl)-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

benzyl (1R,5R)-6-[3-({[1-(2,3-dichlorophenyl)-1H-tetrazol-5-yl]amino}methyl)pyridin-2-yl]-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate;

N-({2-[(1S,5R)-3,6-diazabicyclo[3.2.0]hept-6-yl]pyridin-3-yl}methyl)-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichlorophenyl)-N-({2-[(3aR,7aS)-octahydro-2H-4,7-epoxyisoindol-2-yl]pyridin-3-yl}methyl)-1H-tetrazol-5-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-(6′-fluoro-[2,3′]bipyridinyl-3-ylmethyl)-amine;

[1-(2,3-Dichloro-4-fluorophenyl)-1H-tetrazol-5-yl](2′-fluoro-[2,4′]bipyridinyl-3-ylmethyl)amine;

[2-(1-Benzyl-1H-pyrazol-4-yl)pyridin-3-ylmethyl]-[1-(2,3-dichloro-4-fluorophenyl)-1H-tetrazol-5-yl]amine;

[1-(2,3-Dichloro-4-fluorophenyl)-1H-tetrazol-5-yl](2-methylpyridin-3-ylmethyl)amine;

[1-(4-Chloro-3-trifluoromethylphenyl)-1H-tetrazol-5-yl](6′-fluoro-[2,3′]bipyridinyl-3-ylmethyl)amine;

3-{5-[(6′-Fluoro-[2,3′]bipyridinyl-3-ylmethyl)amino]tetrazol-1-yl}benzonitrile;

1′-Benzyl-3-{[1-(2,3-dichloro-4-fluoro-phenyl)-1H-tetrazol-5-ylamino]-methyl}-1′H-[2,4′]bipyridinyl-2′-one;

(2-Chloro-pyridin-3-ylmethyl)-[1-(2,3-dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-amine;

[1-(2,3-Dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-(2′-fluoro-[2,3′]bipyridinyl-3-ylmethyl)-amine;

[1-(2,3-Dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl](2-pyrimidin-5-yl-pyridin-3-ylmethyl)amine;

4-(3-{[1-(2,3-Dichloro-4-fluorophenyl)-1H-tetrazol-5-ylamino]methyl}pyridin-2-yl)-[1,4]diazepane-1-carboxylic acid tert-butyl ester;

(2-[1,4]Diazepan-1-yl-pyridin-3-ylmethyl)-[1-(2,3-dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-amine;

[1-(2,3-Dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-[2-(4-isopropyl-[1,4]diazepan-1-yl)-pyridin-3-ylmethyl]-amine;

[1-(2,3-Dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-[2-(4-isobutyl-[1,4]diazepan-1-yl)-pyridin-3-ylmethyl]-amine;

[2-(4-Cyclopropylmethyl-[1,4]diazepan-1-yl)-pyridin-3-ylmethyl]-[1-(2,3-dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-amine;

[1-(2,3-Dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-{2-[4-(2,2-dimethyl-propyl)-[1,4]diazepan-1-yl]-pyridin-3-ylmethyl}-amine;

[1-(2,3-Dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-[2-(4-propyl-[1,4]diazepan-1-yl)-pyridin-3-ylmethyl]-amine;

[1-(2,3-Dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-{2-[4-(3,3,3-trifluoro-propyl)-[1,4]diazepan-1-yl]-pyridin-3-ylmethyl}-amine;

[1-(2,3-Dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-{2-[4-(tetrahydro-pyran-4-ylmethyl)-[1,4]diazepan-1-yl]-pyridin-3-ylmethyl}-amine;

[2-(4-Cyclopentyl-[1,4]diazepan-1-yl)-pyridin-3-ylmethyl]-[1-(2,3-dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-amine;

[1-(2,3-Dichloro-4-fluoro-phenyl)-1H-tetrazol-5-yl]-{2-[4-(tetrahydro-pyran-4-yl)-[1,4]diazepan-1-yl]-pyridin-3-ylmethyl}-amine;

1-(2,3-dichlorophenyl)-N-[(2,4-dimethylpyridin-3-yl)methyl]-1H-tetrazol-5-amine;

1-(2,3-dichloro-4-fluorophenyl)-N-({2-[4-(methylsulfonyl)-1,4-diazepan-1-yl]pyridin-3-yl}methyl)-1H-tetrazol-5-amine;

ethyl {4-[3-({[1-(2,3-dichloro-4-fluorophenyl)-1H-tetrazol-5-yl]amino}methyl)pyridin-2-yl]-1,4-diazepan-1-yl}acetate;

N-{[2-(4-acetyl-1,4-diazepan-1-yl)pyridin-3-yl]methyl}-1-(2,3-dichloro-4-fluorophenyl)-1H-tetrazol-5-amine;

1-(2,3-dichloro-4-fluorophenyl)-N-[(2-{4-[(dimethylamino)acetyl]-1,4-diazepan-1-yl}pyridin-3-yl)methyl]-1H-tetrazol-5-amine;

4-[3-({[1-(2,3-dichloro-4-fluorophenyl)-1H-tetrazol-5-yl]amino}methyl)pyridin-2-yl]-N,N-dimethyl-1,4-diazepane-1-sulfonamide;

[1-(2,3-Dichloro-4-fluorophenyl)-1H-tetrazol-5-yl][2-(6-fluoropyridin-3-yloxy)pyridin-3-ylmethyl]amine;

[1-(2,3-Dichloro-4-fluorophenyl)-1H-tetrazol-5-yl][2-(2-fluoropyridin-3-yloxy)pyridin-3-ylmethyl]amine;

[1-(2,3-Dichlorophenyl)-1H-tetrazol-5-yl]-[2-(2-fluoropyridin-3-yloxy)pyridin-3-ylmethyl]amine;

4-(3-{[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-ylamino]-methyl}-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-(2-piperazin-1-yl-pyridin-3-ylmethyl)amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[2-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[2-(4-propyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[2-(4-isopropyl-[1,4]diazepan-1-yl)-pyridin-3-ylmethyl]-amine;

[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-yl]-[2-(4-propyl-[1,4]diazepan-1-yl)-pyridin-3-ylmethyl]-amine;

2-[4-(3-{[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-ylamino]-methyl}-pyridin-2-yl)-[1,4]diazepan-1-yl]-acetamide;

2-[4-(3-{[1-(2,3-Dichloro-phenyl)-1H-tetrazol-5-ylamino]-methyl}-pyridin-2-yl)-piperazin-1-yl]-acetamide; and

2-{4-[3-({[1-(2,3-dichloro-4-fluorophenyl)-1H-tetrazol-5-yl]amino}methyl)pyridin-2-yl]-1,4-diazepan-1-yl}acetamide.

9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or 2 , or a therapeutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. A method for treating chronic inflammatory pain or neuropathic pain comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 9 .

11. A method for treating chronic inflammatory pain or neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1 or 2 , or a therapeutically acceptable salt thereof.

12. A method for inhibiting P2X 7 activity comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1 or 2 , or a therapeutically acceptable salt thereof.

13. A method for treating inflammation and inflammatory pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1 or 2 , or a therapeutically acceptable salt thereof.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013

From: ABBOTT LABORATORIES

To: ABBVIE INC.

Reel/Frame 030182/0547 →